Cargando...

Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux

Gefitinib is an orally active inhibitor of the epidermal growth factor receptor approved for use in patients with locally advanced or metastatic non–small cell lung cancer. It has also been evaluated in several clinical trials for treatment of brain tumors such as high-grade glioma. In this study, w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Agarwal, Sagar, Sane, Ramola, Gallardo, Jose L., Ohlfest, John R., Elmquist, William F.
Formato: Artigo
Idioma:Inglês
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2010
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2912048/
https://ncbi.nlm.nih.gov/pubmed/20421331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.110.167601
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!